Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Foncology%2Fsabcs-2021%2Finducers-of-ferroptosis-are-potential-drugs-to-target-p53-mutated-tnbc-cells%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=3.93.74.25&categories=Conference+Report+Article%7CBreast+Cancer%7CSABCS+2021%7CBasic+and+Translational+Research%7COncology&conference=SABCS+2021): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells - Medical Conferences

Home > Oncology > SABCS 2021 > Basic and Translational Research > Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells

Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells

Presented By
Dr William Tahaney, MD Anderson Cancer Center, TX, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021

Expression of a mutant p53-gene sensitises triple-negative breast cancer (TNBC) cells to death by ferroptosis. The experimental drug ML-162 induces ferroptosis in p53-mutated TNBCs and demonstrated anti-cancer activity in vitro and in vivo.

Up to 85% of TNBCs have a p53 mutation as their oncogenic driver. Due to this high frequency of p53 mutations in TNBCs, targeting p53 mutants in a clinical setting could be highly attractive if pathways exist that, when inhibited, will induce the specific death of p53-mutant breast cancer cells, but not p53-wild type breast cells. Dr William Tahaney (MD Anderson Cancer Center, TX, USA) presented first results of the search for these pathways and drugs that can inhibit them [1].

In vitro and in silico drug screens identified 6 potential drugs that inhibit growth of p53-mutant TNBCs but not p53-wild type TNBCs. One drug, the perodixase inhibitor ML-162, was selected for further study and was found to induce death through ferroptosis, and not apoptosis or necroptosis. The effect of ML-162 was demonstrated in vivo by treating p53-mutant TNBC xenografts in nude mice with ML-162. This treatment significantly reduced tumour volume and induced lipid peroxidation, a hallmark of ferroptosis.

“In conclusion, our high-throughput screening demonstrated that several of the identified drugs suppress growth or induce death preferentially in p53-mutant TNBCs. One of these drugs, ML-162, induces death of p53-mutant TNBCs through induction of ferroptosis. Therefore, these studies provide the basic science foundation to further develop ferroptosis inducers for the targeted treatment of p53-mutant breast cancers,” concluded Dr Tahaney.

  1. Tahaney WM, et al. Inhibition of GPX4 induces preferential death of p53-mutant triple-negative breast cancer cells. GS1-09, SABCS 2021 Virtual Meeting, 7–10 December.

Copyright ©2022 Medicom Medical Publishers



Posted on